O

Om Research LLC | Lancaster, CA

Research site
(Unclaimed)
Location
44215 15th Street West, Suite 203, Lancaster, California, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

19 of 35
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Enrolling
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Placebo
Drug: Semaglutide

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old...

Enrolling
Ulcerative Colitis
Drug: SHR0302
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Enrolling
Colitis, Ulcerative
Drug: Placebo
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 2
Drug: Guselkumab Dose 1

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Other: Placebo
Drug: Guselkumab Dose 1

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participant...

Active, not recruiting
Celiac Disease
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Drug: TAK-062 Placebo

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Guselkumab Dose 3
Drug: Ustekinumab

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Enrolling
Primary Sclerosing Cholangitis
Drug: Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 80 mg

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: Mirikizumab

The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or...

Enrolling
Eosinophilic Gastrointestinal Disease
Eosinophilic Gastritis
Drug: Matching Placebo
Drug: Dupilumab Dose 2

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Enrolling
Ulcerative Colitis
Drug: Etrasimod
Locations recently updated

This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of S...

Enrolling
Colitis Ulcerative
Drug: Placebo
Drug: SAR443122

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)
Locations recently updated

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Enrolling
Primary Biliary Cholangitis
Drug: Placebo
Drug: Seladelpar 10 mg

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the effi...

Active, not recruiting
Cirrhosis
Prevention of Esophageal Varices
Drug: belapectin
Drug: Placebo
Locations recently updated

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderat...

Enrolling
Ulcerative Colitis
Drug: Tilpisertib Fosmecarbil
Drug: Placebo

Trial conditions

Colitis (10 trials)
Ulcer (10 trials)
Ulcerative Colitis (10 trials)
Fatty Liver (6 trials)
Non-alcoholic Fatty Live... (6 trials)
Gastroparesis (4 trials)
Fibrosis (3 trials)
Liver Diseases (3 trials)
Cholangitis (2 trials)
Compulsive Personality D... (2 trials)

And 23 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems